Literature DB >> 16220065

Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.

James M McKenney1, Michael H Davidson, Joseph Saponaro, Paul D Thompson, Harold E Bays.   

Abstract

This multicenter, 8-week, single-step titration, open-label study sought to assess the percentage of subjects who achieved their National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III low-density lipoprotein (LDL)-cholesterol target when assigned a starting dose of atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg) selected using an algorithm based on their 10-year CHD risk and the magnitude of LDL-cholesterol lowering necessary to reach goal. Following an 8-week washout period, 1298 subjects, categorized as low, medium, or high risk, were assigned to 4 weeks of treatment with a starting dose of atorvastatin selected by the algorithm. At week 4, subjects who did not achieve goal (15.8%) were titrated to the next-higher dose. The primary endpoint was the percentage of subjects in each risk group who achieved LDL-cholesterol goal at week 8. At 8 weeks, 84.8% of subjects (low risk 92.9%; moderate risk 84.0%; high risk 81.1%) achieved LDL-cholesterol target. The majority of patients (84.2%) achieved their lipid target through the use of the algorithm-based starting dose (10-80 mg) without the need for titration. No patient had elevations in creatine phosphokinase >10 times the upper limit of normal. Elevations in alanine aminotransaminase or aspartate aminotransaminase were observed in <1% of study subjects and were unrelated to dose. Selecting the starting dose of atorvastatin using a treatment algorithm achieves NCEP ATP III LDL-cholesterol goals in the majority of patients and minimizes the need for dose titration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220065     DOI: 10.1097/01.fjc.0000180901.70607.72

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

1.  Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.

Authors:  Deepak Voora; Svati H Shah; Carol R Reed; Jun Zhai; David R Crosslin; Chad Messer; Benjamin A Salisbury; Geoffrey S Ginsburg
Journal:  Circ Cardiovasc Genet       Date:  2008-12-09

2.  Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?

Authors:  James R Clem; Joe D Strain; Debra K Farver
Journal:  Risk Manag Healthc Policy       Date:  2009-12-22

3.  Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes.

Authors:  Jang Won Son; Dong Jun Kim; Chang Beom Lee; Seungjoon Oh; Kee-Ho Song; Chan Hee Jung; Ji Oh Mok; Jong Hwa Kim; Min Kyong Moon; Kyung Mook Choi; Jae Hyoung Cho; Sung Hee Choi; Soo Kyung Kim; Kang Seo Park; Hye Soon Kim; In Joo Kim; Young Il Kim; Hae Jin Kim; Sang Yong Kim; Sungrae Kim
Journal:  J Diabetes Investig       Date:  2013-03-26       Impact factor: 4.232

4.  Lipid goal attainment and prescription behavior in asian patients with acute coronary syndromes: experience from a tertiary hospital.

Authors:  Calvin W Chin; F Gao; Tt Le; Rs Tan
Journal:  Clin Med Insights Cardiol       Date:  2013-03-12

Review 5.  Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.

Authors:  Enas A Enas; Arun Kuruvila; Pravien Khanna; C S Pitchumoni; Viswanathan Mohan
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.